Stay updated with breaking news from Robertb Stein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which i...
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY...
Protagenic Therapeutics Achieves First Clinical Safety Milestone with ...